Abstract
Spinal cord injury (SCI) is a long-lasting damage in the spinal cord that leads to paraparesis, paraplegia, quadriplegia and other lifetime disabilities. The underlying mechanisms responsible for the failure of axonal regeneration after SCI remain only partially understood. Although a spectrum of medical treatments has been made available for this disease, the therapeutic effects remain disappointing. The emergence of antibody treatment has paved a new pathway for the management of SCI. In this current review, we summarized the application of antibodies in SCI in studies of myelin repair, neuroprotection, axon outgrowth, and anti-immune reaction. In the meantime, the combination treatment of the antibody with other reagents or stem cell transplant was also reviewed.
Keywords: Antibody, spinal cord injury, neuroprotective, myelin repair, anti-immune reaction, neuropathic pain
Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Therapeutic Antibodies for Spinal Cord Injury
Volume: 16 Issue: 1
Author(s): Dan-yang Tang and Wei-jiang Zhao
Affiliation:
Keywords: Antibody, spinal cord injury, neuroprotective, myelin repair, anti-immune reaction, neuropathic pain
Abstract: Spinal cord injury (SCI) is a long-lasting damage in the spinal cord that leads to paraparesis, paraplegia, quadriplegia and other lifetime disabilities. The underlying mechanisms responsible for the failure of axonal regeneration after SCI remain only partially understood. Although a spectrum of medical treatments has been made available for this disease, the therapeutic effects remain disappointing. The emergence of antibody treatment has paved a new pathway for the management of SCI. In this current review, we summarized the application of antibodies in SCI in studies of myelin repair, neuroprotection, axon outgrowth, and anti-immune reaction. In the meantime, the combination treatment of the antibody with other reagents or stem cell transplant was also reviewed.
Export Options
About this article
Cite this article as:
Tang Dan-yang and Zhao Wei-jiang, Therapeutic Antibodies for Spinal Cord Injury, CNS & Neurological Disorders - Drug Targets 2017; 16 (1) . https://dx.doi.org/10.2174/1871527315666160915150754
DOI https://dx.doi.org/10.2174/1871527315666160915150754 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipopolysaccharide-Induced Chorioamnionitis Causes Acute Inflammatory Changes in the Ovine Central Nervous System
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: An Update on Neurotrophins (Guest Editor: Celia Duarte Cruz)]
Current Neuropharmacology Neurological Disorders of Purine and Pyrimidine Metabolism
Current Topics in Medicinal Chemistry Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Clinical Trials in Relapsing-Remitting Multiple Sclerosis /A New Proposal for Dealing with Basic Problems and Restrictions/
Reviews on Recent Clinical Trials Transcranial Magnetic Stimulation on Rodent Models
CNS & Neurological Disorders - Drug Targets Current Updates on Bone Grafting Biomaterials and Recombinant Human Growth Factors Implanted Biotherapy for Spinal Fusion: A Review of Human Clinical Studies
Current Drug Delivery Amyotrophic Lateral Sclerosis: A Genetic Point of View
Current Molecular Medicine Pharmacological Intervention of Cyclooxygenase-2 and 5-Lipoxygenase Pathways. Impact on Inflammation and Cancer
Current Pharmaceutical Design Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Berberine Administration in Treatment of Colitis: A Review
Current Drug Targets The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Intrathecal Enzyme Replacement Therapy for Mucopolysaccharidosis I: Translating Success in Animal Models to Patients
Current Pharmaceutical Biotechnology Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued) The Honolulu-Asia Aging Study: Epidemiologic and Neuropathologic Research on Cognitive Impairment
Current Alzheimer Research Brain Delivery of Chemotherapeutics in Brain Cancer
Anti-Cancer Agents in Medicinal Chemistry Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets Radiation-Induced Neuroinflammation and Radiation Somnolence Syndrome
CNS & Neurological Disorders - Drug Targets Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry